News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.
A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.
PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.
Pfizer, GitLab, and Conoco Phillips shares surged to 52-week highs on Wednesday amid a series of positive company catalysts and optimistic Wall Street coverage.
The company is coming back into the spotlight thanks to recent developments.
With central banks lifting interest rates to tackle inflation, investors are hunting for themes that do not rely purely on cheap money to grow. Artificial intelligence in healthcare is one such story. It focuses on software and data rather than heavy assets. This article highlights three Transformative AI Healthcare Stocks from our screener that apply algorithms to diagnostics, treatment decisions, and hospital efficiency. The three stocks that follow are only a starting sample from this...
Patient investors who buy the stock may be rewarded over the long term.
Nike's first-quarter earnings will have some investors trying to read between the lines to gauge the impact of a new CFO and what's next for turnaround plans.
Pfizer gained on vaccine and oncology growth, MiniMed on strong earnings, and Deere on AI-driven agriculture.
Three blue-chip CFO swaps touched off double-digit stock rallies while Rivian's announcement landed with a thud. The difference comes down to one decision Rivian has yet to make.
Pfizer (NYSE:PFE) has reached a confidential settlement covering federal lawsuits over its Depo-Provera contraceptive and alleged intracranial meningioma risk. The agreement reportedly addresses more than 6,000 cases, with financial terms not disclosed and no admission of liability by Pfizer. The resolution closes a multi year legal overhang tied to Depo-Provera and brings clarity to a significant product liability dispute. This kind of large scale legal settlement can shift how investors...
As investors hedge against AI-trade valuation worries, dividend payers gain favor. AT&T, ONEOK, and Pfizer offer yields from 4.3% to 6.1% with distinct capital-return strategies.
PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.
Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously.
PFE has underperformed the broader market over the past year, while analysts remain moderately optimistic about its future prospects.
The XFG-adapted vaccine targets older and high-risk patients, with deliveries to pharmacies and clinics beginning immediately.
BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical
BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's melanoma triumph, and the fallout is forcing investors to rethink how far mRNA technology can actually reach into solid tumors.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
David Ellison needed more legal muscle. After Paramount suffered a bruising July hearing in its fight with a coalition of state attorneys general trying to block its $81 billion acquisition of Warner Bros. Discovery Ellison picked up the phone and called a lawyer used to hearing from CEOs in a jam: Beth Wilkinson. Wilkinson has successfully defended the National Football League and pharmaceutical giant Pfizer as well as Supreme Court Justice Brett Kavanaugh against accusations of sexual assault in his confirmation hearings, making her a go-to trial lawyer in high-stakes cases.
Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell on Friday. Shares of Alnylam (NASDAQ: ALNY) fell nearly 4.9% in pre-market trading following the full presentation of data from a rival drug trial at the European Society of Cardiology Congress in Munich. The detailed results from AstraZeneca and Ionis Pharmaceu
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.